Fig. 2
From: PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer
Loss of function or inhibition of PLK4 enhances RT induced anticancer effects. Combination of the PLK4 knockdown and RT demonstrates increased anticancer effects, compared to single-agent treatments in (A) MDA-MB-468, (B) MDA-MB-231 and (C) SUM159 cells transfected with either scrambled control (scr) or PLK4-targeting siRNA (siPLK4) and treated with RT (p ≤ 0.05 compared to control (*), RT (α) or siPLK4 (β) only). Combination treatment of (D) MDA-MB-468, (E) MDA-MB-231 and (F) SUM159 cells with RT and PLK4 inhibitor Centrinone B results in decreased colony formation compared to control (*), RT (α) or Centrinone B (β) only (n = 3, p ≤ 0.05). CB– Centrinone B, RT– Radiotherapy, SF– Surviving Fraction